GLYCOPHOS 4.32 g/20 mL (Sodium Glycerophosphate Ampoules) 4.32 g/20 mL

Glycophos 4.32 g/20 mL ampoules provide phosphate supplementation in clinical settings. This sterile solution supports metabolic functions and is commonly used for patients requiring intravenous phosphate therapy. Store below 25°C to maintain stability.

Strength

4.32 g/20 mL

Pack Size

20s

Storage

Below 25°C

Manufacturer / TM Owner

fresenius Kabi

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Sodium glycerophosphate is used to address phosphate deficiencies in patients unable to obtain adequate amounts through diet or oral supplements. It is often administered in hospital or clinical environments where intravenous phosphate therapy is required. This medication helps restore normal phosphate levels, supporting bone health and muscle function.

Side Effects

When administered as directed, sodium glycerophosphate ampoules help restore phosphate balance in the body. Patients may experience improved energy levels and muscle function as phosphate levels normalize. The solution is designed for intravenous use and is typically well-tolerated when used appropriately.

Precautions & Warnings

Glycophos ampoules should only be used under medical supervision. Patients with kidney disease or conditions affecting phosphate metabolism should use this product cautiously. Ensure proper storage below 25°C and inspect the solution for clarity before administration. Always follow healthcare provider instructions for use.

Avoid Interactions

Sodium glycerophosphate may interact with medications affecting kidney function or phosphate balance, such as diuretics or calcium supplements. Concurrent use with other intravenous solutions should be monitored to avoid potential imbalances. Patients should inform their healthcare provider about all medications and supplements they are taking.

Frequently Asked Questions

It is used to treat phosphate deficiencies in patients who cannot get enough phosphate through diet or oral supplements.

Glycophos is administered intravenously under medical supervision.

No, this medication is intended for use in clinical settings only.

Store below 25°C and protect from light to maintain product integrity.

Side effects are rare when used as directed, but patients may experience mild discomfort at the injection site.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.